SCHEMBL1265327

SCHEMBL1265327

NCc1nccc(-c2cccnc2Cl)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 4/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 3/20 0.37
LMNA P02545 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
RECQL P46063 1/20 0.36
C1S P09871 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HPGD P15428 1/20 0.36
DHODH Q02127 1/20 0.36
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503736 0.78 CDK5 (0.53) NPC1RAB9AKDM4EALDH1A1CDC7
SCHEMBL446754 0.78 NPC1 (0.41) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL581004 0.77 DPP4 (0.40) DPP4NPC1RAB9AMEN1KMT2A
SCHEMBL3613252 0.77 LOXL2 (0.47) NPC1RAB9ADHODHGABRA1ALOX5AP
SCHEMBL1265121 0.73 DPP4 (0.39) DPP4NPC1RAB9AMEN1KMT2A
SCHEMBL28295771 0.71 ASIC3 (0.44) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL16460200 0.71 TGFBR1 (0.52) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL580408 0.71 DYRK1A (0.52) HDAC8
SCHEMBL16473314 0.71 PDPK1 (0.38) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL580322 0.71 LMNA (0.56) NPC1RAB9AMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751136-B1 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC (US) 2014-07-02 EP disclosed
US-8476434-B2 Protein kinase modulators and method of use AMGEN INC. (US) 2013-07-02 US disclosed
US-20110201602-A1 PROTEIN KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2011-08-18 US disclosed
US-7880000-B2 N-(5-(1,1- dimethylethyl)-3- isoxazolyl)-4-methyl-3- ((3-(4-pyrimidinyl)-2- pyridinyl)amino)benzamide, used for treating breast cancer or rheumatoid arthritis AMGEN INC. (US) 2011-02-01 US disclosed
EP-1751136-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-02-14 EP disclosed
US-20060009453-A1 Protein kinase modulators and method of use AMGEN INC. 2006-01-12 US disclosed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009453-A1 Protein kinase modulators and method of use PHKG1, PRKCH, BMP2K DPP4 2859/4885NPC1 4619/4885RAB9A 1773/4885
US-20110201602-A1 PROTEIN KINASE MODULATORS AND METHOD OF USE GRK4, MAP4K5, GRK5 DPP4 2776/4885NPC1 4497/4885RAB9A 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.